Carlsmed, Inc. (Nasdaq: CARL) reported a remarkable second quarter with revenue reaching $12.1 million, showcasing a significant 99% year-over-year growth.
The company's AI-enabled personalized spine surgery solutions continue to drive commercial success, with a full-year revenue guidance of $45.5M - $47.5M.
The successful launch of the aprevo® technology platform and ongoing advancements in personalized spine surgery set a positive trajectory for Carlsmed.
Revenue Growth
Revenue in the second quarter surged by 99% compared to the previous year, fueled by increased utilization of the aprevo® technology platform.
Financial Performance
Gross profit for the quarter was $8.9 million, with a gross margin of 73.4%, driven by revenue growth despite increased operating expenses.
Strategic Expansion
Carlsmed's expansion into personalized cervical spine surgery and receiving CMS NTAP reimbursement reinforce the company's position as an industry leader.
Cash Position
As of June 30, 2025, Carlsmed held $33.5 million in cash and received $93.5 million from its recent IPO, ensuring strong financial footing for future growth.
- The 99% revenue growth reflects strong market acceptance of Carlsmed's innovative technology and underscores the company's potential for becoming a standard in spine fusion surgery.
- Despite increased operating expenses, Carlsmed's gross margin remained robust at 73.4%, showcasing efficient cost management strategies amid growth initiatives.
Carlsmed's outstanding performance in the second quarter of 2025, coupled with strategic advancements in personalized spine surgery, positions the company for continued success and growth in the evolving healthcare market.